相关实验视频

Updated: Sep 17, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

在与免疫相关的不良事件发生后,恢复免疫检查点抑制剂治疗

Hirotaka Suto¹

¹Department of Medical Oncology, Hyogo Cancer Center, Hyogo, Japan hirotaka.suto@hyogo-cc.jp.

In vivo (Athens, Greece)

|June 27, 2025

概括

免疫检查点抑制剂 (ICI) 的免疫相关不良事件 (irAEs) 可以在治疗后持续存在. 本综述考察了在irrAEs后恢复ICI治疗的风险和益处,指导临床决策.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

免疫相关不良事件 (irAEs) 是与免疫检查点抑制剂 (ICI) 相关的一类不良事件.
这些事件模仿自身免疫性疾病,可以影响多个器官.
与传统化疗的副作用不同,irrAEs甚至在ICI治疗停止后也可能持续或复发.

研究的目的:

审查与恢复免疫检查点抑制剂 (ICI) 治疗在免疫相关不良事件 (irAEs) 后相关的风险和益处.
总结一下在IRAE之后重新管理ICI的程序性考虑.

主要方法:

文献综述,重点关注临床数据和专家的共识,关于iREs后的ICI重新挑战.
影响irAE复发和对再治疗的反应的因素分析.
综合指导方针,用于管理经历了irAEs的患者.

主要成果:

伊雷发作复发的风险受最初伊雷发作的类型和严重程度的影响.
患者对重新服用ICI的反应取决于特定的药物及其序列.
仔细的风险益处评估对于决定是否恢复ICI治疗至关重要.

结论:

在irAEs之后恢复ICI治疗需要基于个体患者因素的个性化方法.
了解irAEs和ICI重新挑战的细微差别对于优化癌症治疗结果至关重要.
本综述为管理符合ICI再挑战资格的患者的临床医生提供了一个框架.

关键词:

免疫检查点抑制剂重新挑战这是一种皮质类固醇.与免疫相关的不良事件免疫调节器是一种免疫调节器.审查审查审查审查审查审查

更多相关视频

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...